On March 13, 2024, Zephyr AI, Inc. closed the transaction. The company has received $111,354,487 in the transaction pursuant to exemption provided under Regulation D. The transaction included participation from 30 investors including new investors Eli Lilly and Company, EPIQ Capital Group, LLC, Revolution Growth, individual investor Jeff Skoll and other investors.
Market Closed -
Other stock markets
|
After market 01:48:32 am | |||
760 USD | -1.50% | 763 | +0.39% |
09:46pm | Cipla Open to Partner With Eli Lilly to Market Obesity Drugs in India | MT |
07:42pm | Roughly 1 in 8 US adults have taken GLP-1 drugs like Wegovy, poll shows | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.38% | 695B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 330B | |
+3.73% | 283B | |
+16.70% | 239B | |
+8.78% | 204B | |
-7.93% | 198B | |
+7.68% | 168B | |
+5.09% | 125B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Zephyr AI, Inc. announced that it has received $111.354487 million in funding from Eli Lilly and Company, EPIQ Capital Group, LLC, Revolution Growth and other investors